Quantcast
Last updated on April 21, 2014 at 9:29 EDT

Latest Nootropics Stories

2012-03-05 23:11:37

Immaturity may lead to diagnosis of disorder The youngest children in the classroom are significantly more likely to be diagnosed with attention-deficit/hyperactivity disorder (ADHD) – and prescribed medication – than their peers in the same grade, according to a study just published in CMAJ (Canadian Medical Association Journal). ADHD, which is often treated with prescription medication, is the most commonly diagnosed behavioural disorder in children. Two recent studies...

2012-02-27 11:03:06

People who take Ritalin are far more aware of their mistakes, a University of Melbourne study has found. The study, by Dr Rob Hester from the Department of Psychological Sciences and colleagues at the Queensland Brain Institute, investigated how the brain monitors ongoing behavior for performance errors — specifically failures of impulse control. It found that a single dose of methylphenidate (Ritalin) results in significantly greater activity in the brain´s error monitoring...

2012-02-08 14:29:25

Reports new study in Journal of the American Academy of Child and Adolescent Psychiatry Attention-deficit/hyperactivity disorder (ADHD) affects 5-9% of youth and is frequently treated with stimulant medications, such as methylphenidate and amphetamine products. A recent safety communication from the US Food and Drug Administration advised that all patients undergoing ADHD treatment be monitored for changes in heart rate or blood pressure. Amidst growing concern over the risks of...

2012-02-08 10:25:54

A 7-decades mystery solved It has long been known that psychostimulant drugs have the paradoxical effect of reducing hyperactivity. [Psychostimulant drugs include methylphenidate — known by the trade names Ritalin, Concerta, and Methylin — and methamphetamine]. Since the mid-1950s, millions of children and adults have been prescribed stimulant medications to control attention deficit hyperactivity disorder (ADHD). But for more than seven decades, since the first experiment that...

2012-02-07 11:37:00

PHILADELPHIA, Feb. 7, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) as a maintenance treatment for adults with ADHD. The approval is based on results from a randomized withdrawal study designed to evaluate the efficacy of Vyvanse in adults (aged 18 to 55 years) who...

2012-02-07 11:15:00

PHILADELPHIA, February 7, 2012 /PRNewswire/ -- Vyvanse (lisdexamfetamine dimesylate), an approved treatment forAttention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 and above, is the first medication both proven to work and approved for maintenance treatment in adults with ADHD Shire plc [http://www.shire.com/shireplc/en/home ] (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug...

2012-02-02 06:30:00

MIAMI, Feb. 2, 2012 /PRNewswire/ -- Insero Health, Inc., a company developing novel therapies derived from natural products, today announced that it has closed an initial financing round. The company also announced that it has exclusively licensed key patents from Harvard University for the use of Insero's lead compound huperzine as a treatment for epilepsy and other indications. Huperzine is sourced from a naturally occurring botanical extract that has been used for centuries in...

2012-01-27 19:30:00

According to NeuroGenesis, a Texas based supplements manufacturer, recently pharmacies in many American States have experienced a major drug shortage, leaving hundreds of thousands of ADHD patients and patients with related illnesses to find alternatives to traditional medicine. League City, TX (PRWEB) January 27, 2012 According to NeuroGenesis, an all natural supplements manufacturer and the American Medical Association (AMA) recently pharmacies throughout the country have experienced a...

2012-01-19 08:28:00

PITTSBURGH, Jan. 19, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Mylan Institutional business has launched Levetiracetam in Sodium Chloride Injection, 500 mg/100 mL, 1000 mg/100 mL and 1500 mg/100 mL, for intravenous use. Mylan's launch of this new product, which has been approved by the U.S. Food and Drug Administration (FDA), marks the first time that multiple strengths (500 mg, 1000 mg and 1500 mg) of premixed Levetiracetam will be supplied...

ADHD Drugs Do Not Up Risk For Heart Problems
2011-12-13 06:15:34

Researchers, funded by the U.S. Food and Drug Administration and the Agency for Health Research Quality, recently studied the cardiovascular risk of ADHD medications in adults. The study found little evidence that the medications increased the risk of heart events, such as heart attack, sudden cardiac death, and stroke. The concerns stem from the fact that some of the medications are able to slightly increase heart rate and blood pressure levels. According to the study,...